FB-418 is under clinical development by 1St Bio Therapeutics and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FB-418’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FB-418 overview

FB-418 is under development for the treatment of Parkinson’s disease and amyotrophic lateral sclerosis (ALS). The therapeutic candidate acts by targeting leucine-rich repeat kinase 2 (LRRK2) and c Abl protein. It is administered through oral route.

1St Bio Therapeutics overview

1st Bio Therapeutics (1st Bio) is a healthcare company that provide treatment for degenerative brain diseases. The company is headquartered in Seongnam-si, Gyeonggi-do, South Korea.

For a complete picture of FB-418’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.